Spyre Therapeutics, Inc. (SYRE)
85.81
+0.12
(+0.14%)
USD |
NASDAQ |
Oct 12, 12:22
Spyre Therapeutics Free Cash Flow (Quarterly) : -70.16M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -70.16M |
| March 31, 2026 | -57.54M |
| December 31, 2025 | -44.65M |
| September 30, 2025 | -37.12M |
| June 30, 2025 | -46.56M |
| March 31, 2025 | -41.09M |
| December 31, 2024 | -37.53M |
| September 30, 2024 | -29.50M |
| June 30, 2024 | -62.25M |
| March 31, 2024 | -28.54M |
| December 31, 2023 | -31.04M |
| September 30, 2023 | -34.60M |
| June 30, 2023 | -16.64M |
| March 31, 2023 | -17.63M |
| December 31, 2022 | -18.14M |
| September 30, 2022 | -15.07M |
| June 30, 2022 | -20.67M |
| March 31, 2022 | -26.30M |
| December 31, 2021 | -19.27M |
| September 30, 2021 | -17.09M |
| June 30, 2021 | 2.052M |
| March 31, 2021 | -19.98M |
| December 31, 2020 | -18.13M |
| Date | Value |
|---|---|
| September 30, 2020 | -18.10M |
| June 30, 2020 | -20.74M |
| March 31, 2020 | -23.08M |
| December 31, 2019 | -17.47M |
| September 30, 2019 | -17.35M |
| June 30, 2019 | -16.44M |
| March 31, 2019 | -15.92M |
| December 31, 2018 | -7.403M |
| September 30, 2018 | -8.603M |
| June 30, 2018 | -9.079M |
| March 31, 2018 | -7.53M |
| December 31, 2017 | -6.064M |
| September 30, 2017 | -7.479M |
| June 30, 2017 | -5.988M |
| March 31, 2017 | -5.703M |
| December 31, 2016 | -4.476M |
| September 30, 2016 | -5.865M |
| June 30, 2016 | -4.721M |
| March 31, 2016 | -3.99M |
| December 31, 2015 | -0.873M |
| September 30, 2015 | -3.945M |
| June 30, 2015 | -3.879M |
| March 31, 2015 | -2.493M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| AbbVie, Inc. | 3.114B |
| Incyte Corp. | 495.25M |
| SELLAS Life Sciences Group, Inc. | -7.588M |
| Relay Therapeutics, Inc. | -54.11M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |